1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Long-Term Intramuscular Administration of Thyrotropin-Releasing Hormone Tartrate in Patients with Cerebrovascular Disease: Effects on the Pituitary-Thyroid Axis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We studied the effects of long-term (30 days) refracted daily intramuscular administration of 4 mg TRH tartrate (TRH-T) on the pituitary-thyroid axis in 20 euthyroid patients affected by cerebrovascular disease (CVD). All subjects were assayed for T<sub>4</sub>, T<sub>3</sub>, FT<sub>4</sub>, FT<sub>3</sub>, TSH and TBG plasma levels before treatment (D<sub>o</sub>), after 15 and 30 treatment days (D<sub>15</sub>, D<sub>30</sub>), and after a 15-day washout (D<sub>45</sub>). In addition, TSH response to 200 µg intravenous TRH was assessed at D<sub>o</sub>, D<sub>30</sub> and D45. We observed a significant increase in T<sub>4</sub>, FT<sub>4</sub> and FT3 levels in the face of decreased TSH concentrations. A blunted TSH response to TRH bolus persisted at D<sub>30</sub>. These data demonstrate that the down-regulation mechanism may be partially overcome in vivo when thyrotrophs are chronically exposed to pharmacological TRH-T doses and that TSH pattern is mainly due to the negative feedback of thyroid hormones, even though pituitary TSH reserves may become depleted. Furthermore, prolonged TRH-T administration does not produce hyperthyroidism in euthyroid CVD patients.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          1663-2818
          1663-2826
          1991
          1991
          02 December 2008
          : 35
          : 3-4
          : 146-150
          Affiliations
          aClinica Medica II and bClinica Medica I, Università di Pisa, Italia
          Article
          181891 Horm Res 1991;35:146–150
          10.1159/000181891
          1806468
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Comments

          Comment on this article